OBJECTIVE: Cytochrome P450 17alpha-hydroxylases-C-(17,20)-lyase (CYP17) is a key enzyme involved with the androgen biosynthesis pathway and has recently been targeted for therapy in men with advanced prostate cancer (PCa). However, studies relating prostate cancer outcomes with CYP17 gene variants have conflicting results. In this study we analyzed Single Nucleotide Polymorphisms (SNPs) spanning the CYP17 gene for association with PCa survival. METHODS: The cohort was comprised of Caucasian men, aged 40-64, diagnosed with PCa between 1993 and 1996 in King County, Washington who participated in a population-based case-control study. CYP17 SNPs were selected to capture variation across the gene and known regulatory regions. PCa-specific mortality (PCSM) was obtained by linking to the SEER cancer registry. Recurrence/progression of PCa was determined from patient survey data and medical records. Cox proportional hazards regression analysis was used to generate hazard ratios for patient outcomes. RESULTS: Genotypes were available for 598 cases. With a median follow-up of 13.2 years, 44 PCa deaths were observed. Recurrence/progression events were observed in 30% of subjects. No genetic association with disease progression were identified. However, men with the variant A allele in rs10883783 had a 56% risk reduction in PCSM (HR 0.44, 95% CI 0.21-0.98). CONCLUSION: These data suggest that genetic variation in the CYP17 gene in Caucasian men is associated with PCa survival.
OBJECTIVE:Cytochrome P450 17alpha-hydroxylases-C-(17,20)-lyase (CYP17) is a key enzyme involved with the androgen biosynthesis pathway and has recently been targeted for therapy in men with advanced prostate cancer (PCa). However, studies relating prostate cancer outcomes with CYP17 gene variants have conflicting results. In this study we analyzed Single Nucleotide Polymorphisms (SNPs) spanning the CYP17 gene for association with PCa survival. METHODS: The cohort was comprised of Caucasian men, aged 40-64, diagnosed with PCa between 1993 and 1996 in King County, Washington who participated in a population-based case-control study. CYP17 SNPs were selected to capture variation across the gene and known regulatory regions. PCa-specific mortality (PCSM) was obtained by linking to the SEER cancer registry. Recurrence/progression of PCa was determined from patient survey data and medical records. Cox proportional hazards regression analysis was used to generate hazard ratios for patient outcomes. RESULTS: Genotypes were available for 598 cases. With a median follow-up of 13.2 years, 44 PCa deaths were observed. Recurrence/progression events were observed in 30% of subjects. No genetic association with disease progression were identified. However, men with the variant A allele in rs10883783 had a 56% risk reduction in PCSM (HR 0.44, 95% CI 0.21-0.98). CONCLUSION: These data suggest that genetic variation in the CYP17 gene in Caucasian men is associated with PCa survival.
Authors: Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-03 Impact factor: 4.254
Authors: Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: A H Carey; D Waterworth; K Patel; D White; J Little; P Novelli; S Franks; R Williamson Journal: Hum Mol Genet Date: 1994-10 Impact factor: 6.150
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono Journal: J Clin Oncol Date: 2008-07-21 Impact factor: 44.544
Authors: Jonathan L Wright; Erika M Kwon; Elaine A Ostrander; R Bruce Montgomery; Daniel W Lin; Robert Vessella; Janet L Stanford; Elahe A Mostaghel Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-25 Impact factor: 4.254
Authors: Milan S Geybels; Marian L Neuhouser; Jonathan L Wright; Marni Stott-Miller; Janet L Stanford Journal: Cancer Causes Control Date: 2013-08-02 Impact factor: 2.506
Authors: Daniel W Lin; Liesel M FitzGerald; Rong Fu; Erika M Kwon; Siqun Lilly Zheng; Suzanne Kolb; Fredrik Wiklund; Pär Stattin; William B Isaacs; Jianfeng Xu; Elaine A Ostrander; Ziding Feng; Henrik Grönberg; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-08-16 Impact factor: 4.254
Authors: Milan S Geybels; Jonathan L Wright; Sarah K Holt; Suzanne Kolb; Ziding Feng; Janet L Stanford Journal: Prostate Date: 2013-04-30 Impact factor: 4.104
Authors: Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi Journal: Biochim Biophys Acta Date: 2014-09-06
Authors: C J Ryan; W Peng; T Kheoh; E Welkowsky; C M Haqq; D W Chandler; H I Scher; A Molina Journal: Prostate Cancer Prostatic Dis Date: 2014-03-18 Impact factor: 5.554
Authors: Anna M Aschelter; Silvana Giacinti; Paola Caporello; Paolo Marchetti Journal: Front Endocrinol (Lausanne) Date: 2012-11-06 Impact factor: 5.555